---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Effects of other drugs"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Effects of other drugs. Topics: CYP3A4 and P-glycoprotein substrate, Rifampin and itraconazole drug interaction study in healthy adults, Strong CYP3A and P-gp inducer: rifampin, Strong CYP3A4 and P-gp inhibitor: itraconazole; moderate CYP3A4 inhibitor: cyclosporine, and 2 further topics. 6 evidence topics quoted from 2 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/effects-of-other-drugs"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Effects of other drugs

<a id="heading-2.1.2.9.1"></a>

## 2.1.2.9.1 Effects of Other Drugs on Inaxaplin

<a id="topic-2.1.2.9.1-1"></a>

### CYP3A4 and P-glycoprotein substrate

> “In vitro studies indicated VX-147 is substrate for CYP3A4 and P-gp.”
> “Therefore, it is anticipated that drugs that inhibit or induce CYP3A4 and P-gp could have an impact on the PK of VX-147.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-2.1.2.9.1-2"></a>

### Rifampin and itraconazole drug interaction study in healthy adults

> “was done to evaluate the effect of rifampin, a strong CYP3A and P-gp inducer, and itraconazole, a strong CYP3A4 and P-gp inhibitor, on single dose PK of VX-147”
> “DDI study in 28 healthy male and female subjects (14 subjects in the itraconazole group and 14 subjects in the rifampin group).”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-2.1.2.9.1-3"></a>

### Strong CYP3A and P-gp inducer: rifampin

> “Administration of rifampin resulted in a significant decrease in VX-147 exposure: AUC0-∞ GMR (90% CI) 0.154 (0.139, 0.170) and Cmax GMR (90% CI) 0.552 (0.498, 0.612) relative to VX-147 administration alone.”
> “These results indicate that strong CYP3A4 inducers have the potential to significantly decrease VX-147 exposure.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-2.1.2.9.1-4"></a>

### Strong CYP3A4 and P-gp inhibitor: itraconazole; moderate CYP3A4 inhibitor: cyclosporine

> “Administration of itraconazole resulted in a smaller change (approximately 2-fold) compared to rifampin.”
> “VX-147 AUC0-∞ increased with a GMR (90% CI) of 1.98 (1.79, 2.19), while Cmax increased slightly, GMR of 1.14 (1.07, 1.20) compared to VX-147 administration alone.”
> “These results indicate that strong CYP3A4 inhibitors are unlikely to cause a significant increase (>2-fold) in VX-147 exposure, and that a moderate CYP3A4 inhibitor, such as cyclosporine, is expected to result in a less than 2-fold increase in AUC0-24h,ss.”
> “Hence, cyclosporine administration is anticipated to be safe if co-administered with a 45 mg qd dose of VX-147.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-2.1.2.9.1-5"></a>

### Restricted medications and foods in the phase 2a study

| Restriction | Start | Stop |
| --- | --- | --- |
| CYP3A4 inhibitors or inducers | “None allowed within 14 days before the first dose of the study drug” | “Completion of Safety Follow-up Visit assessments” |
| Grapefruit and related fruits | “7 days before first dose of study drug” | “Until last PK sample is taken” |

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

> “Moderate and strong CYP3A4 inhibitors or inducers, including consumption of herbal medications (e.g., St. John’s Wort)”
> “Grapefruit, grapefruit juice, pomelos, orange marmalade, Seville/blood oranges”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-2.1.2.9.1-6"></a>

### QT-prolonging concomitant medications excluded from AMPLITUDE

> “Risk factors for Torsade de Pointes (e.g., familial long QT syndrome, chronic hypokalemia, heart failure) or concomitant medications that prolong the QT/QTc interval or any history of cardiac disorders”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
